NCT01867775Unknown3 期
Mirtazapine for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Double-blind, Placebo-controlled Study
Brasilia University Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2012年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Change From Baseline in Nighttime Total Sleep Time
研究概览
简要总结
The purpose of this study is to determine whether mirtazapine is effective in the treatment of sleep disorders in Alzheimers disease.
详细描述
Mirtazapine has been used for depressed elderly with sleep disorders with good tolerability and efficacy. The study hypothesis is that mirtazapine could also be used in demented with sleep disorders.
Sleep disorders (SD) affects 35 to 50 percent of patients with Alzheimer Disease (AD). These disorders often make caring for patients at home very difficult and It's also associated with higher risk of institutionalization and increases health care costs. Treatment of SD in people with dementia may benefit both patients and their caregivers. However, little is known about the efficacy of pharmacological treatments for treating sleep disturbances in AD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fifty-five years of age or older; Diagnosis of probable Alzheimer's disease by National Institute of Neurological and Communicative Disorders and Stroke/the Alzheimer's Disease and Related Disorders Association criteria; Hachinski Ischemia Scale score less than 5 Mini-Mental State Examination score of O to 26 Actigraph evidence of a mean time immobile of less than 7 hours per night based on at least 7 nights of complete actigraph data collected over a single week; For-week history of sleep disorder behaviors, occurring at least once weekly, as reported by the caregiver using the Neuropsychiatric Inventory (NPI) Nighttime Behavior scale; Sleep disturbance observed was not present before the diagnosis of AD; Other co-morbidities, especially delirium, depression, chronic pain and medication use may be present, but do not cooperate in the primary symptoms; Computed tomography or magnetic resonance imaging since the onset of memory problems showing no more than 1 lacunar infarct in a nonstrategic area and no clinical events suggestive of stroke or other intracranial disease or normal; Stable medications for 4 weeks prior to the screening visit; Having a mobile upper extremity to which to attach an actigraph; Residing with a responsible spouse, family member, or professional caregiver who is present during the night and would agree to assume the role of the principal caregiver for the 3-week protocol; Ability to ingest oral medication and participate in all scheduled evaluations
排除标准
- •Sleep disturbance associated with an acute illness, delirium or psychiatric disease; Clinically significant movement disorder, such as akinesia, that would affect actigraphic differentiation of sleep and wakefulness Severe agitation; Unstable medical condition; Discontinuation of psychotropic or sleep medications within 2 weeks of the screening visit; Patient unwilling to maintain caffeine abstinence after 2:00 PM for the duration of the protocol; Patient unwilling to comply with the maximum limit of 2 alcoholic drinks per day, and only 1 alcoholic drink after 6:00 PM for the duration of the protocol; Prior use of mirtazapine for the treatment of sleep disturbances; Caregiver deemed too unreliable to supervise the wearing of the actigraph, to administer trazodone the proper time, to maintain tbe sleep diary, or to bring the patient to the scheduled visits;
研究组 & 干预措施
Mirtazapine
Active Comparator
Mirtazapine, 15 mg once a day, at night for 14 days
干预措施: Mirtazapine (Drug)
结局指标
主要结局
Change From Baseline in Nighttime Total Sleep Time
时间窗: Baseline, 14 days follow-up
Mean of Nighttime Total Sleep Time (in minutes) during the 12-h nocturnal epoch 8:00 PM - 08:00 AM after 2 weeks under treatment
次要结局
- Change From Baseline in Nighttime Number Of Awakenings(Baseline, 14 days follow-up)
- Change From Baseline in in Daytime Total Sleep Time(Baseline, 14 days follow-up)
- Change From Baseline in Nighttime Wake After Sleep Onset(Baseline, 14 days follow-up)
- Change From Baseline in Number of Daytime Naps(Baseline, 14 days follow-up])
- Change in Cognitive Function (as Measured by the Mini-Mental State Examination)(Baseline, 14 days follow-up])
- Change in Activities of Daily Living (The Index of ADL - Katz)(Baseline, 14 days follow-up])
- Change of Baseline in Behavioral Variables (BAHAVE-AD Scale)(Baseline, 14 days follow-up])
- Change From Baseline in Cognitive Function (Digit Symbol Substitution Test)(Baseline, 14 days follow-up])
研究者
Einstein Francisco de Camargos
Medical Doctor
Brasilia University Hospital
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Role of Mirtazapine in Ameliorating Sleep Disordered BreathingSpinal Cord InjuriesSleep Disordered BreathingNCT04799782Wayne State University18
已完成
不适用
Efficacy of mirtazapine for sleep disturbance and anxiety symptoms compared with selective serotonin reuptake inhibitors in patients with major depressive disorder: a multicenter open-label randomized controlled trial.Major depressive disorderJPRN-UMIN000004144Department of Psychiatry, Chiba University Graduate School of Medicine120
已完成
1 期
New Pharmacological Treatment for Obstructive Sleep ApneaObstructive Sleep ApneaNCT00108498US Department of Veterans Affairs
已完成
3 期
Trazodone for Sleep Disorders in Alzheimer's DiseaseSleepSleep DisordersInsomniaAlzheimer's DiseaseNCT01142258Brasilia University Hospital40
进行中（未招募）
2 期
Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZGlioma of BrainNCT03935685University of California, Irvine120